Type 2 automated insulin delivery Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines automated insulin delivery, meaning pumps and algorithms that read a glucose sensor and adjust insulin dosing with little input from the user, and how these systems are moving from type 1 diabetes to the much larger group of people with type 2 diabetes who use insulin. It tests how far coverage, clearances and over-the-counter sensors can carry that move by 2034.

The user base is the first argument. Insulet states that about 6 million people in the United States with type 2 diabetes take insulin and about 2.5 million of them take multiple daily injections, and it received FDA clearance on 26 August 2024 for Omnipod 5 in adults with type 2 diabetes, with HbA1c falling by 0.8 percentage points and time in range rising by about 20 percent in a 13 week trial. The conclusion is that the type 2 insulin population is several times larger than the type 1 population served so far, so each point of adoption adds large volume.

Clearances followed across the market in 2026. On 2 February 2026 the FDA cleared the MiniMed 780G for insulin-requiring type 2 diabetes with the Abbott Instinct sensor and Medicare access was opened, and on 18 March 2026 MiniMed received clearance for the MiniMed Flex, a pump about half the size of the 780G, for type 1 from age 7 and insulin-requiring type 2 from age 18. The conclusion is that type 2 is now a standard indication for new systems, and size and ease of use are the next points of competition.

Sensors are moving to the pharmacy counter. Dexcom received FDA clearance in June 2026 for Stelo, an over-the-counter sensor, for ages 2 and above including people who take oral medicines but not insulin, with wear of up to 15 days. The conclusion is that a larger group of people will hold glucose data before insulin starts, which prepares the ground for automated systems when they do.

The brief treats type 2 automated insulin delivery as a high-impact signal with an eight year horizon to 2034. It identifies which systems and companies move first and what each means for device makers, clinicians and payers. It is a focused 109-page decision brief that presents an indicative trajectory rather than a segmented market model.

An automated insulin delivery system links a glucose sensor, an insulin pump and a dosing algorithm. The algorithm reads sensor values, predicts where glucose is heading and adjusts the basal rate or gives correction doses, so the user no longer sets each dose by hand. MiniMed states that its SmartGuard algorithm adjusts delivery every 5 minutes, which shows how often the system acts.

Interoperability is changing how systems are built. The FDA cleared SmartGuard as an interoperable automated glycaemic controller and the MiniMed 780G as an alternate controller enabled pump, allowing use with the Abbott Instinct sensor, and Sequel plans a choice of embedded Loop or the Diabeloop algorithm in the twiist system. The conclusion is that pumps, sensors and algorithms from different makers can be combined, which widens choice and lowers the cost of entry for new makers.

Form factor is the second change. Modular Medical received clearance in April 2026 for the Pivot tubeless patch pump, which has a battery that lasts 90 days and a 300 unit cartridge that lasts three days, and Tandem reports that users of Control-IQ+ in type 1 pregnancy spent about three more hours a day in the pregnancy target range. The conclusion is that smaller devices and special populations are widening who can use automated systems.

Over-the-counter sensing feeds the funnel. Dexcom Stelo is cleared for ages 2 and above including people who do not use insulin, and the company previewed its G8 sensor in May 2026, about half the size of the G7, with FDA submission planned for 2027. The conclusion is that sensor data will reach many more people than pumps, so prescription systems benefit from earlier awareness.

The limits are reimbursement and pharmacy access, clinician time for training, device safety actions and the evidence for type 2 outcomes. In March 2026 Insulet corrected certain Omnipod 5 pod lots that could leak and the FDA issued a warning letter to Beta Bionics over complaint handling for the iLet, and the brief tests each limit against the cost trajectory to 2034.

The automated insulin delivery market, covering insulin pumps and patch pumps with automated dosing algorithms and their pods, cartridges and infusion sets for people with type 1 and insulin-requiring type 2 diabetes, and excluding standalone glucose sensors, manual insulin pumps, insulin drugs, smart pens and diabetes software sold separately, is valued at USD 7.0–9.0 billion in 2026 and is projected to reach USD 16.13–20.74 billion by 2034, at a CAGR of 11%.

The 2026 base rests on automated pumps, patch pumps and their consumables sold in the United States, Europe, Japan and other markets with sensor-augmented insulin delivery. Growth then follows type 2 coverage, new users of insulin who start on automated systems and the spread of smaller devices.

The forecast is sensitive to Medicare and payer coverage for type 2, the rate at which clinicians prescribe pumps and the safety record of new devices.

The base case assumes Medicare and large payers cover automated systems for insulin-using type 2 patients by 2028 and over-the-counter sensors widen the funnel, bringing the inflection to about 2029 and a 2034 value near the middle of the range. An accelerated case assumes strong type 2 outcome data and primary care prescribing, bringing the inflection to 2027 and lifting the 2034 value to the top of the range. A delayed case assumes slow coverage and safety setbacks, moving the inflection to 2032 and holding growth at the bottom of the range.

Growth drivers

• Insulin-using type 2 population.
• Glycaemic outcomes.
• Over-the-counter sensor adoption.
• Pregnancy and paediatric indications.

Enablers

• Sensor and pump interoperability.
• Smaller pumps and patch designs.
• Coverage decisions.
• Data platforms.

Restraints and barriers

• Reimbursement and pharmacy access.
• Clinician time and training.
• Device safety actions.
• Skills.

The direction of automated insulin delivery is set by clearances for type 2, over-the-counter sensors, the size of the insulin-using population, smaller devices and payer coverage.

The key participants in automated insulin delivery include Insulet Corporation, Tandem Diabetes Care, Inc., MiniMed Group, Inc., Beta Bionics, Inc., Sequel Med Tech, LLC, Modular Medical, Inc., Dexcom, Inc., Abbott Laboratories, Medtrum Technologies Inc., Ypsomed Holding AG, Roche Holding AG, Diabeloop SA, Embecta Corp., Senseonics Holdings, Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Glooko, Inc., Dario Health Corp., Tidepool, Ascensia Diabetes Care Holdings AG, i-SENS, Inc., SOOIL Development Co., Ltd., Biolinq, Inc., Zealand Pharma A/S, UnitedHealth Group Incorporated, CVS Health Corporation, The Cigna Group, Elevance Health, Inc., Humana Inc., the Centers for Medicare & Medicaid Services, American Diabetes Association, Breakthrough T1D, International Diabetes Federation, Jaeb Center for Health Research, Mayo Clinic and Stanford Medicine.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as type 2 adoption grows.

Insulet, Tandem, MiniMed, Beta Bionics and Sequel lead among system makers, Dexcom and Abbott among sensor makers, and Diabeloop, Glooko and Tidepool among algorithm and data platform companies. Competitive intensity is high among pump makers and rising as sensors and algorithms from different makers combine.

Where value migrates.

In 2026 value sits with pump makers that hold clearances and pharmacy access, because they supply the systems that insulin users receive first. By 2029 it moves toward systems that combine sensors, algorithms and pumps from different makers, and toward companies that reach type 2 users through primary care. By 2034 it settles with automated delivery as the default way to take insulin, where data and consumables carry the margin. Margins hold for makers with type 2 clearance and strong consumables, and narrow for makers of single-purpose pumps without sensor partners.

The signals converge on a market where clearances are in place and access is the next step. Type 2 clearances across platforms, Medicare access for the MiniMed 780G and over-the-counter sensors support growth, while reimbursement, clinician time and device safety actions hold back adoption.

Structural limits show where progress could slow: coverage criteria for type 2, the capacity of clinics to train new users, the safety record of new devices and the outcome evidence in type 2. The brief therefore tracks four indicators: users on automated systems, payer coverage decisions, type 2 trial results and device safety actions.

Cleared systems first, then broader coverage and over-the-counter sensors, then automated delivery as standard insulin therapy is the expected order of change.